TCT Calatayud-Noguera

T Calatayud-Noguera

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


T Calatayud-Noguera has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 28 May 2009
      • Vol. 48  (11) , 582-4

    [Rivastigmine in a case of autopsy proved frontotemporal dementia (Pick's disease)].

    by T Calatayud-Noguera, A Astudillo-González, J C Alvarez-Carriles, T Temprano-Fernández, M Cortés-Velarde, P Oliva-Nacarino

    Cholinesterase inhibitors are useful in the treatment of behavioural and psychological symptoms in Alzheimer's disease. Their effectiveness in frontotemporal dementia has not been proved, since such a claim has only been backed by the publication of one open-label trial in which the behavioural and psychological symptoms of the patients treated with rivastigmine over a 12-month period improved significantly with respect to those belonging to a group that were given a placebo. We report a case of frontotemporal dementia, Pick's disease, which improved with rivastigmine treatment. A 61-year-old male who presented a progressive clinical picture of behavioural disorders and executive-cognitive impairment that had begun two years earlier. Magnetic resonance imaging of the head revealed severe frontotemporal atrophy. Neuropsychological Inventory (NPI). Overall score 36/144 (6/12: anxiety, disinhibition and aberrant motor behaviour, 4/12: agitation, irritability and apathy; 3/12: sleep and eating disorders. After three months' treatment with rivastigmine, the overall score on the NPI was 10/144. This improvement remained stable over the months that followed. The patient died eight months later after developing liver cancer with metastasis. The microscopic study of the brain showed tau-positive neuronal inclusions, gliosis and neuronal loss. The inclusions were well-circumscribed Pick bodies, which were present in the frontal and temporal cortices and in the dentate gyrus of the hippocampus. This case confirms the idea that treatment with cholinesterase inhibitors can be effective in the behavioural and psychological symptoms of frontotemporal dementia.

  • Open Access

    Plasmatic level of neurosin predicts outcome of mild cognitive impairment

    by Manuel Menendez-Gonzalez, Patricia Castro-Santos, Maria T Calatayud, Pablo Perez-Piñera, Renee Ribacoba, Marta Martinez-Rivera, Carmen Gutierrez, Alfonso Lopez-Muñiz, Ana Suarez

    Mild Cognitive Impairment (MCI) is a disorder considered to be a transitional stage from health to dementia. Diagnosis of dementias at these early stages is always troublesome because the pathophysiologic events leading to dementia precede clinical symptoms. Thus, the development of biomarkers that can be used to support the diagnosis of dementias at early stages is rapidly becoming a high priority. We have recently reported the value of measuring plasmatic levels of neurosin in the diagnosis of Alzheimer's disease (AD). The aim of this study is to determine whether measuring plasmatic concentration of neurosin is a valuable test to predict progression of MCI.